Date:12/3/2012

nd integrating third-party licensed technology; acceptance of the Company's marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing, exploiting and defending our intellectual property rights including those pertaining uncertainties associated with doing business internationally across borders and territories; and additional risks inherent in development stage businesses. Healthcare Holdings Group, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:
Investor Relations:
Mr. Lenny Tambasco, CEO
info(at)healthcareholdingsgroup(dot)com
http://www.healthcareholdingsgroup.com

Read the full story at http://www.prweb.com/releases/2012/12/prweb10196531.htm.

'/>"/>

Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes
3. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
4. A molecule central to diabetes is uncovered
5. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
6. Novo Nordisk To Award $80,000 To Local Programs That Help People Living With Diabetes In Detroit As Part Of Educational Initiative
7. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
8. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
9. Low testosterone levels could raise diabetes risk for men
10. New Findings of Daily Consumption of Soy Isoflavones and Cacao-Flavonoids in Diabetes Type 2 Patients
11. Gut Microbiota Transplantation may Prevent Development of Diabetes and Fatty Liver Disease